Sanofi SA

SNY

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2024

    Employees

    87,994

Sanofi SA News & Analysis

stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks

10 best US blue-chip shares to buy for the long term

The stocks of these high-quality companies with large market capitalizations look undervalued today.
personal-finance

Can you achieve global diversification with multinational companies?

A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,567.0012.10-0.14%
CAC 407,213.3214.870.21%
DAX 4019,146.17141.390.74%
Dow JONES (US)43,792.38383.910.88%
FTSE 1008,149.2764.200.79%
HKSE19,601.11103.90-0.53%
NASDAQ18,930.8035.34-0.19%
Nikkei 22538,026.17326.17-0.85%
NZX 50 Index12,765.2428.180.22%
S&P 5005,936.5719.460.33%
S&P/ASX 2008,323.003.30-0.04%
SSE Composite Index3,370.402.410.07%

Market Movers